CLYYF (Celyad Oncology) Institutional Ownership: 0.18% (As of Jul. 06, 2026)


CLYYF Celyad Oncology SA CLYYF
13 GF Score
Price $0.25
GF Value $0.47
! 6 Warning Signs
View Full Analysis

What is Celyad Oncology Institutional Ownership?

Celyad Oncology CLYYF 13 Institutional Ownership is 0.18% as of Jul. 06, 2026. GuruFocus rates CLYYF with a GF Score™ of 13/100 and a GF Value™ of $0.47. The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Celyad Oncology's institutional ownership is 0.18%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Celyad Oncology's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Celyad Oncology's Float Percentage Of Total Shares Outstanding is 0.00%.

Celyad Oncology Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Celyad Oncology's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celyad Oncology Institutional Ownership Chart

Celyad Oncology Historical Data

The historical data trend for Celyad Oncology can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 0.13 0.10 0.08 0.07 0.07 0.06 0.06 0.06 0.06 0.06
CLYYF
13GF Score
Celyad Oncology SA CLYYF
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celyad Oncology Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.18% mean?
Celyad Oncology (CLYYF) has a Institutional Ownership of 0.18% as of Jul. 06, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Celyad Oncology and its competitors.
Is Celyad Oncology's Institutional Ownership too high?
Celyad Oncology's current Institutional Ownership is 0.18%. Overall, Celyad Oncology has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's Institutional Ownership compare to VRTX and REGN?
Celyad Oncology's Institutional Ownership of 0.18% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Celyad Oncology and its competitors. Celyad Oncology's current Institutional Ownership is 0.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Celyad Oncology (CLYYF) has a current Institutional Ownership of 0.18%. The stock's GF Value™ is $0.47, compared to a current price of $0.25 — trading 46.8% below its estimated fair value. The current Institutional Ownership is 0.18%. Celyad Oncology's overall GF Score™ is 13/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current Institutional Ownership is 0.18% as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celyad Oncology (CLYYF) Overvalued in 2026?

Based on GuruFocus' analysis, Celyad Oncology stock appears to be undervalued. The current stock price of $0.25 is trading 46.8% below its estimated GF Value™ of $0.47.

Key valuation signals for CLYYF:

  • Institutional Ownership: 0.18%
  • GF Value™: $0.47 vs. price of $0.25 (46.8% below fair value)
  • GF Score™: 13/100 with 6 warning signs

No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celyad Oncology Business Description

Address Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
13GF Score

Get the complete analysis for CLYYF

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price
$0.47
GF Value